Lyric Pharmaceuticals Gets $20.4M For GI Disease Research
South San Francisco-based Lyric Pharmaceuticals, a company developing therapeutics for gastrointestinal diseases, said last week that it has raised $20.4M in a Series A financing round. The funding was led by Rivervest Venture Partners, Sante Ventures, and Third Point Ventures, and also included Aperture Venture Partners. The firm's founders are David Wurtman and M. Scott Harris.
posted on Monday, March 2, 2015
Related companies:
Lyric Hospitality, Inc.
Related stories:
> Alvine Pharmaceuticals Acquired By ImmunogenX
> Arriva Pharmaceuticals Adds $6M
> Neuraltus Pharmaceuticals Finds $17M
> KAI Pharmaceuticals Acquired By Amgen For $315M
> Edison Pharmaceuticals Nabs $20M To Treat Mitochondrial Disease
silicontap.com Home